Drug Profile
Dihydroergotamine mesilate inhalation - AbbVie
Alternative Names: DHE-inhalation - MAP; Levadex®; MAP 0004; SEMPRANALatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Developer AbbVie
- Class Antimigraines; Ergotamines; Mesylates; Small molecules
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Migraine
Highest Development Phases
- No development reported Migraine
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 31 Jul 2019 No development reported - Phase-II for Migraine (In adolescents) (Inhalation)
- 31 Jul 2019 No development reported - Phase-III for Migraine (Inhalation)